[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nuvation Bio Inc (NUVB)

Nuvation Bio Inc (NUVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,643,513
  • Shares Outstanding, K 348,202
  • Annual Sales, $ 62,900 K
  • Annual Income, $ -204,630 K
  • EBIT $ -150 M
  • EBITDA $ -148 M
  • 60-Month Beta 1.52
  • Price/Sales 27.12
  • Price/Cash Flow N/A
  • Price/Book 5.34

Options Overview Details

View History
  • Implied Volatility 92.62% (-116.29%)
  • Historical Volatility 64.84%
  • IV Percentile 31%
  • IV Rank 8.23%
  • IV High 369.46% on 03/27/26
  • IV Low 67.79% on 07/22/25
  • Expected Move (DTE 14) 0.48 (9.21%)
  • Put/Call Vol Ratio 0.57
  • Today's Volume 1,263
  • Volume Avg (30-Day) 652
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 33,910
  • Open Int (30-Day) 32,130
  • Expected Range 4.69 to 5.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.15
  • Number of Estimates 3
  • High Estimate $-0.14
  • Low Estimate $-0.16
  • Prior Year $-0.17
  • Growth Rate Est. (year over year) +11.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.07 +27.03%
on 05/19/26
5.41 -4.44%
on 06/04/26
+0.76 (+17.23%)
since 05/04/26
3-Month
4.05 +27.81%
on 03/30/26
5.41 -4.44%
on 06/04/26
+0.43 (+9.07%)
since 03/04/26
52-Week
1.57 +229.30%
on 06/16/25
9.75 -46.97%
on 12/22/25
+2.72 (+111.02%)
since 06/04/25

Most Recent Stories

More News
Nuvation Bio to Present at the Jefferies Global Healthcare Conference

NEW YORK , May 27, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David...

NUVB : 5.17 (+9.53%)
Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting

  88% of TRUST-II patients reported improved or stable quality of life at first assessment, with the majority sustaining that benefit throughout treatment

NUVB : 5.17 (+9.53%)
Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer

Thermo Fisher Scientific, the world leader in serving science, will now manufacture drug product for Nuvation Bio in the United States

NUVB : 5.17 (+9.53%)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Nuvation Bio Inc. (NYSE: NUVB)

NEW YORK , May 7, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Nuvation Bio Inc. (NYSE: NUVB) on behalf of the company's shareholders. The investigation seeks to...

NUVB : 5.17 (+9.53%)
Nuvation Bio to Participate in Upcoming Investor Conferences

NEW YORK , May 5, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David...

NUVB : 5.17 (+9.53%)
Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Achieved $18.5 million in first quarter of 2026 net product revenues for IBTROZI ® (taletrectinib); majority of the approximately 200 patients started on IBTROZI in the first...

NUVB : 5.17 (+9.53%)
Can Nuvation Bio's Pipeline Finally Prove the Skeptics Wrong About Its Valuation?

Barchart Research What to Expect from NUVB Earnings NUVB Generated May 1, 2026 Current Price $4.49 EPS Estimate $$0.12 Consensus Rating Strong Buy Average Move 6.61% Can Nuvation Bio's Pipeline Finally...

NUVB : 5.17 (+9.53%)
Can Nuvation Bio's Pipeline Finally Prove the Skeptics Wrong About Its Valuation?

Barchart Research What to Expect from NUVB Earnings NUVB Generated May 1, 2026 Current Price $4.49 EPS Estimate $$0.12 Consensus Rating Strong Buy Average Move 6.61% Can Nuvation Bio's Pipeline Finally...

NUVB : 5.17 (+9.53%)
Can Nuvation Bio's Pipeline Finally Prove the Skeptics Wrong About Its Valuation?

Barchart Research What to Expect from NUVB Earnings NUVB Generated May 1, 2026 Current Price $4.49 EPS Estimate $$0.12 Consensus Rating Strong Buy Average Move 6.61% Can Nuvation Bio's Pipeline Finally...

NUVB : 5.17 (+9.53%)
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers

Guidelines include the next-generation targeted therapy as a systemic option for patients with ROS1-positive non-small cell lung cancer with brain metastases

NUVB : 5.17 (+9.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Nuvation Bio Inc. is a biopharmaceutical company. It engages in developing differentiated and novel therapeutic candidates for unmet needs in oncology. Nuvation Bio Inc., formerly known as Panacea Acquisition Corp., is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 6.17
2nd Resistance Point 5.79
1st Resistance Point 5.48
Last Price 5.17
1st Support Level 4.79
2nd Support Level 4.41
3rd Support Level 4.10

See More

52-Week High 9.75
Fibonacci 61.8% 6.63
Fibonacci 50% 5.66
Last Price 5.17
Fibonacci 38.2% 4.69
52-Week Low 1.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.